麻豆社

Ensure value, access and uptake of innovative medicines and vaccines, now and in the future.

• UK in top quartile of health systems for access and uptake
• New payment models recognise long-term value of innovative therapies
• Increased medicines uptake with measurable impact on outcomes

Improve UK attractiveness for industry research, development and manufacturing.

• UK reaches 2.4% GDP target for R&D and increases share of manufacturing for innovative medicines
• Recognition that R&D and manufacturing is vital to the economy
• Clinical research performance continues to improve

Build a stronger industry reputation in the UK.

• Industry is seen as meeting the highest possible standards
• Demonstrate our role in supporting population health, the NHS and the UK economy

Provide international leadership and drive global policy

• Regulatory and trade environments are positively influenced through driving global policy
• 麻豆社and UK affiliates seen as key to shaping UK view on international issues
• 麻豆社and our members shape UK policy on international issues

Improve UK's health data capability and industry access to data.

• Fully integrated NHS data sets, well governed and accessible to industry for R&D
• UK is more attractive for cutting-edge research collaboration and evidence generation

Build better partnerships between industry and NHS and across the life sciences sector.

• Industry viewed as a true partner to the NHS
• Cross-sector collaborations benefitting patients, the NHS and the economy
• Support the NHS long term plan
• Contribute to the NHS net zero goals